Mon panier

GMP Human Sonic Hedgehog / Shh (C24II) Protein

  • Premium grade (Pre-GMP) version SH7-H5116 is now available for seamless transition.
Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
GMP-SH7H13-50ug
$560.00
GMP-SH7H13-500ug (50ug X 10)
$3660.00
GMP-SH7H13-1mg (50ug X 20)
$5856.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Product Details

    Sonic Hedgehog (SHH) is a morphogen protein that governs cell proliferation, patterning, and differentiation throughout the developing nervous system. During neural differentiation of stem cells, SHH signaling is indispensable for ventralization, specifying the identity of neural progenitor cells along the dorsal-ventral axis. It is particularly vital for generating ventral neuronal subtypes, including motor neurons from the spinal cord and midbrain dopaminergic neurons.

  • Product Features and Advantages

    1. Specific Neuronal Differentiation Driver​: Efficiently induces stem cell differentiation into neuronal progenitor cells and dopaminergic neurons.
    2. Safe Recombinant Expression​: Produced in an E. coli system to ensure high purity and enhanced safety profile.
    3. Long-Term Stability​: Maintains high activity stability with a shelf life of up to 5 years in lyophilized form at -20 °C to -70 °C.
    4. Cost-Effective Solution​: Achieves up to 50% cost reduction compared to conventional alternatives.
  • GMP Platform Advantages

    1. Quality Assurance: Global QMS with comprehensive and stringent QC release criteria.
    2. End-to-End GMP Compliance: Full manufacturing and QC under a cGMP system.
    3. Comprehensive Control of Adventitious Agents: Stringent biosafety from cell banks to final release.
    4. Comprehensive Regulatory Support: Includes RSF and DMF to meet global requirements.
    5. Resilient Supply Chain: Intelligent modular facilities ensure a stable global supply.
    6. Professional Support: Extensive manufacturing and application expertise to accelerate development.
  • Source

    GMP Human Sonic Hedgehog / Shh (C24II) Protein (GMP-SH7H13) is expressed from E. coli cells. It contains AA Cys 24 - Gly 197 (Accession # Q15465-1 (C24II)).

    Request for sequence
  • Molecular Characterization

    Sonic Hedgehog Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries no "tag".

    The protein has a calculated MW of 19.8 kDa. The protein migrates as 23 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).

  • N-terminal Sequence Analysis

    Met-Ile-Ile-Gly-Pro-Gly-Arg-Gly-Phe-Gly-Lys-Arg-Arg-His-Pro
    (Routinely tested)

  • Endotoxin

    Less than 10 EU/mg, tested by the rFC method in compliance with USP <86> and Ph. Eur. 2.6.32.

  • Host Cell Protein

    <0.5 ng/µg of protein tested by ELISA.

  • Host Cell DNA

    <0.02 ng/μg of protein tested by qPCR.

  • Sterility

    Sterility testing was performed using the membrane filtration method in compliance with USP <71> and Ph. Eur. 2.6.1.

  • Mycoplasma

    Negative

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, 60 mM NaCl, pH7.4 with protectants.

    Contact us for customized product form or formulation.

  • Vial Specification

    2R (13 mm neck finish)

  • Shipping

    This product is supplied and shipped with blue ice, please inquire the shipping cost.

  • Storage

    Upon receipt, store it immediately at -20°C or lower for long term storage.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 5 years in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    Sonic Hedgehog SDS-PAGE

    GMP Human Sonic Hedgehog / Shh (C24II) Protein on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • Mass Spectrometry

     Sonic Hedgehog MASS_SPECTROMETRY

    MALDI-TOF analysis of GMP Human Sonic Hedgehog / Shh (C24II) Protein (Cat. No. GMP-SH7H13). The major peak at 19876.734 Da corresponds to the calculated molecular mass, 19814 Da (Routinely tested).

  • Application Data

     Sonic Hedgehog APPLICATION DATA

    GMP Human Sonic Hedgehog / Shh (C24II) Protein (Cat. No. GMP-SH7H13) could induce iPSC derived NPC differentiation, with high expression of NPC markers (PAX6, SOX1, NESTIN) by FACS. This product exhibited similar performance in marker expression with Human Sonic Hedgehog (C24II) Protein, premium grade (Cat. No. SH7-H5116).

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Sonic hedgehog protein (SHH) is also known as HHG-1, which belongs to the hedgehog family. SHH is expressed in fetal intestine, liver, lung, and kidney and not expressed in adult tissues. Sonic hedgehog protein can be cleavage into sonic hedgehog protein N-product and sonic hedgehog protein C-product by autolysis. SHH binds to the patched (PTC) receptor, which functions in association with smoothened (SMO), to activate the transcription of target genes. In the absence of SHH, PTC represses the constitutive signaling activity of SMO. Also regulates another target, the gli oncogene. Intercellular signal essential for a variety of patterning events during development. The C-terminal domain displays an autoproteolysis activity and a cholesterol transferase activity. The N-product is the active species in both local and long-range signaling, whereas the C-product has no signaling activity.

Déclaration importante

  • MANUFACTURING SPECIFICATIONS

    ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP<92>Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP<1043>Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.

    ACROBiosystems Quality Management System Contents:

    1. GMP-certified facility (compliance with FDA cGMP, EMA GMP, ICH, ISO9001/13485/MDSAP, and certified by third-party SGS, UL, and RX360)
    2. Animal origin-free materials, equipments, and facilities
    3. Materials sourced only from approved suppliers
    4. ISO 5 cleanrooms and automatic filling equipment
    5. Professional quality personnel and training programs
    6. Validated analytical testing methods in accordance with the ICH guidelines
    7. Safety Testing (Sterility, Mycoplasma, etc): compliant with USP, EP, etc
    8. In-depth stability studies
    9. Fully batch production and control records
    10. Equipment maintenance and calibration

    Request For Regulatory Support Files (RSF)

    ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

    1. SDS-PAGE
    2. Protein content
    3. Endotoxin level
    4. Residual Host Cell DNA content
    5. Residual Host Cell Protein content
    6. Biological activity analysis
    7. Microbial testing
    8. Mycoplasma testing
    9. In vitro virus assay
    10. Residual moisture
    11. Batch-to-batch consistency

  • ACROBIOSYSTEMS - LEGAL NOTICES FOR GMP GRADE PRODUCTS

    1. PRODUCT USE RESTRICTIONS & PROHIBITIONS

    • 1.1 ACROBiosystems ("ACRO") GMP grade products ("Products") are designed for research, manufacturing use or ex vivo use.
    • 1.2 Products are NOT intended for diagnostic purposes or for direct or indirect administration into humans.
    • 1.3 Purchaser shall not market, distribute, or resell Products obtained from ACRO without ACRO's prior written consent.

    2. REVERSE ENGINEERING PROHIBITED & CONFIDENTIALITY

    • 2.1 Purchaser shall not reverse-engineer, decompile, disassemble, sequence, analyze via bioinformatics, or otherwise attempt to discover the structure, sequence, composition, construction, manufacturing process, or any trade secret embodied in the Products. Purchaser shall not permit any third party to undertake such activities.
    • 2.2 All specifications, data, and know-how related to the Products provided by ACRO are ACRO's confidential information and shall be protected accordingly.

    3. LIMITED WARRANTY & DISCLAIMERS

    • 3.1 ACRO warrants solely that Products will conform to their published specifications when used under normal, specified laboratory/manufacturing conditions and within their labeled expiration date. THIS IS THE ONLY WARRANTY PROVIDED.
    • 3.2 Purchaser assumes ALL risk and responsibility for:
      (a) Determining the suitability of Products for Purchaser's intended application(s).
      (b) Obtaining any necessary regulatory approvals or intellectual property licenses for Purchaser's use.
      (c) Compliance with all applicable laws, regulations (including but not limited to cGMP/GLP where claimed), and industry standards.
      (d) Conducting all necessary quality control, safety, efficacy, and validation testing of Products within Purchaser's process or final product.
      (e) Proper storage, handling, and use of Products according to ACRO's instructions.
    • 3.3 ACRO EXPRESSLY DISCLAIMS ALL OTHER WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, INCLUDING BUT NOT LIMITED TO: (A) WARRANTIES OF MERCHANTABILITY; (B) WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE; (C) WARRANTIES OF NON-INFRINGEMENT; AND (D) WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF TRADE.

    4. LIMITATION OF LIABILITY

    • IN NO EVENT SHALL ACRO, ITS AFFILIATES, OR SUPPLIERS BE LIABLE FOR ANY OF THE FOLLOWING, HOWSOEVER ARISING (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, STATUTE, OR OTHERWISE):
      (a) LOST PROFITS, LOST REVENUE, LOST SAVINGS, LOSS OF USE, LOSS OF DATA, BUSINESS INTERRUPTION, OR ANY OTHER INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES.
      (b) ANY DIRECT DAMAGES, COSTS, OR EXPENSES EXCEEDING THE AMOUNT PAID BY PURCHASER FOR THE SPECIFIC PRODUCT(S) GIVING RISE TO THE CLAIM.
      (c) DAMAGES ARISING FROM: (i) MISUSE, ABUSE, OR UNAUTHORIZED MODIFICATION OF PRODUCTS; (ii) USE BEYOND THE EXPIRATION DATE; (iii) IMPROPER STORAGE OR HANDLING; (iv) ACCIDENTAL DAMAGE; (v) FAILURE TO CONDUCT ADEQUATE VALIDATION OR TESTING BY PURCHASER; (vi) INFRINGEMENT CLAIMS RELATED TO PURCHASER'S USE; OR (vii) THE COST OF PROCURING SUBSTITUTE GOODS OR SERVICES.
      (d) ANY PERSONAL INJURY, DEATH, OR DAMAGE TO TANGIBLE PROPERTY TO THE EXTENT PERMITTED BY LAW.

    5. END USER ACKNOWLEDGEMENT & COMPLIANCE

    • 5.1 By accepting, opening, or using the Products, the End User (Purchaser or its downstream recipient) agrees to be irrevocably bound by all terms herein.
    • 5.2 End User explicitly acknowledges the Products are NOT FOR HUMAN ADMINISTRATION and agrees not to use them in any in vivo human application, directly or indirectly.
    • 5.3 End Users unwilling to accept these terms must immediately: (a) cease all use; (b) notify ACRO or their supplier; and (c) return the unopened, unused Products.
    • 5.4 ACRO reserves the right to audit End User's compliance with these restrictions upon reasonable notice.

    ACRO has the right, at its sole discretion, to modify, add or remove any terms herein without notice to Purchaser and/or End User. Any changes to these terms are effective immediately following the updating of such changes on ACRO’s website or published specifications or product-related documents.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Sonic Hedgehog Homolog

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    4 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte
  • Déclaration importante